NEW YORK (TheStreet) -- Intrexon (XON) - Get Report shares are up 2.56% to $41.25 in after-hours trading after closing intraday trading down 2.05% to $40.22 on Monday following the release of the company's fourth quarter financial results after the closing bell today.

The synthetic biology company reported fourth quarter earnings of $18.8 million, or an adjusted net loss of 6 cents per diluted share on revenue that grew 335% over the same period last year to $31.1 million.

Analysts on average were expecting the Blacksburg, VA-based company to report a net loss of 16 cents per diluted share on revenue of $26.1 million.

For the year the company reported a 203% increase in net revenue to $72 million, with an adjusted EBITDA of $3.2 million and an EPS of 3 cents per diluted share.

"Looking ahead, we are very excited about our near term prospects and have much higher goals for 2015. In Health, we expect to see new major alliances formed, while we believe that our existing ECC partners will be in the clinic with up to ten novel therapeutic candidates. In Food, we anticipate continued growth of our base business with projected product and service revenues exceeding $100M," said CEO Randal Kirk of the company's prospects in 2015.

TheStreet Ratings team rates INTREXON CORP as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate INTREXON CORP (XON) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

• You can view the full analysis from the report here: XON Ratings Report

XON

data by

YCharts